Carbamazepine
Adverse Effect: Decreased carbamazepine plasma concentrations
Clinical Mangement: Monitor closely. Doses of carbamazepine may need to be increased.
Cisplatin
Adverse Effect: Leukemia Clinical Management: Use extreme caution when administering the highly toxic combination, cisplatin and doxorubicin. Digoxin
Adverse Effect: subtherapeutic digoxin plasma concentrations
Clinical Management: Digoxin trough plasma concentrations should be carefully monitored before, during and after Doxorubicin therapy. Alternatively, an equivalent IV dose could be given during the course of cytotoxic therapy.
Phenytoin
Adverse Effect: decreased phenytoin effectiveness Clinical Management: Monitor for evidence of seizure activity during periods of chemotherapy.
Progesterone
Increased doxorubicin-induced neutropenia and thrombocytopenia have been observed when intravenous progesterone (up to 10 g over 24 hours) was administered concurrently with intravenous doxorubicin (60 mg/m2 bolus) to patients with advanced malignancies |